Aclaris Therapeutics Future Growth
Future criteria checks 0/6
Aclaris Therapeutics is forecast to grow earnings and revenue by 1.2% and 3.3% per annum respectively while EPS is expected to grow by 10.7% per annum.
Key information
1.2%
Earnings growth rate
10.7%
EPS growth rate
Pharmaceuticals earnings growth | 14.8% |
Revenue growth rate | 3.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 10 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10 | -84 | -61 | -50 | 5 |
12/31/2025 | 9 | -71 | -57 | -45 | 8 |
12/31/2024 | 8 | -74 | -17 | 67 | 9 |
12/31/2023 | 31 | -88 | -80 | -78 | N/A |
9/30/2023 | 21 | -115 | -92 | -91 | N/A |
6/30/2023 | 31 | -105 | -75 | -74 | N/A |
3/31/2023 | 31 | -96 | -74 | -73 | N/A |
12/31/2022 | 30 | -87 | -68 | -68 | N/A |
9/30/2022 | 24 | -82 | -66 | -66 | N/A |
6/30/2022 | 6 | -83 | -69 | -68 | N/A |
3/31/2022 | 6 | -81 | -61 | -61 | N/A |
12/31/2021 | 7 | -91 | -52 | -52 | N/A |
9/30/2021 | 7 | -82 | -44 | -44 | N/A |
6/30/2021 | 7 | -71 | -46 | -45 | N/A |
3/31/2021 | 7 | -65 | -44 | -44 | N/A |
12/31/2020 | 6 | -51 | -39 | -39 | N/A |
9/30/2020 | 6 | -57 | -51 | -50 | N/A |
6/30/2020 | 6 | -69 | -63 | -61 | N/A |
3/31/2020 | 4 | -102 | -73 | -72 | N/A |
12/31/2019 | 4 | -114 | -98 | -96 | N/A |
9/30/2019 | 5 | -118 | -105 | -103 | N/A |
6/30/2019 | 5 | -115 | -111 | -110 | N/A |
3/31/2019 | 6 | -79 | -112 | -110 | N/A |
12/31/2018 | 6 | -82 | -102 | -101 | N/A |
9/30/2018 | 5 | -81 | -94 | -92 | N/A |
6/30/2018 | 5 | -79 | -77 | -76 | N/A |
3/31/2018 | 3 | -86 | -65 | -64 | N/A |
12/31/2017 | 2 | -50 | -56 | -55 | N/A |
9/30/2017 | 1 | -57 | N/A | -45 | N/A |
6/30/2017 | N/A | -50 | N/A | -41 | N/A |
3/31/2017 | N/A | -48 | N/A | -40 | N/A |
12/31/2016 | N/A | -48 | N/A | -35 | N/A |
9/30/2016 | N/A | -42 | N/A | -31 | N/A |
6/30/2016 | N/A | -42 | N/A | -31 | N/A |
3/31/2016 | N/A | -33 | N/A | -24 | N/A |
12/31/2015 | N/A | -23 | N/A | -20 | N/A |
9/30/2015 | N/A | -21 | N/A | -19 | N/A |
6/30/2015 | N/A | -13 | N/A | -10 | N/A |
3/31/2015 | N/A | -12 | N/A | -9 | N/A |
12/31/2014 | N/A | -11 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0H8T is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0H8T is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0H8T is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0H8T's revenue (3.3% per year) is forecast to grow slower than the UK market (3.4% per year).
High Growth Revenue: 0H8T's revenue (3.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0H8T's Return on Equity is forecast to be high in 3 years time